Curevac no longer pursuing Covid vaccine
The biotech wants to continue researching the underlying method, but is withdrawing its vaccine candidate.
The Tübingen-based biotech start-up Curevac is withdrawing its vaccine candidate from the race. The company announced on Tuesday that it is withdrawing its vaccine CVnCov from the approval process at the European Medicines Agency (Ema). This is the grown-up's response to the recent weak test results for the potential coronavirus vaccine.
The vaccine doses promised to the EU will therefore no longer be delivered and contracts with Bayer, among others, will also lapse. The chemical company was supposed to be responsible for distributing the vaccine.
Despite the setback, the start-up, which has also received millions in funding from the federal government , intends to continue its research with mRNA. Together with GlaxoSmithKline, a large British pharmaceutical company, the company intends to work with so-called modified mRNA in the future, just as Biontech, Pfizer and Moderna have done. The start-up, which was founded in 2000, had previously specialized in unmodified mRNA.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
